The posterior pituitary contains a potent prolactin-releasing factor: in vivo studies.
The posterior pituitary contains a PRL-releasing factor (PRF), a small (less than 5000 mol wt) peptide which is distinct from known PRL secretagogues. The objectives of this study were to determine if posterior pituitary extracts specifically stimulate PRL release in vivo and to assess the relative contributions of oxytocin (OT), arginine vasopressin (AVP), and beta-endorphin (beta END) to the PRF activity of the extract. Rat posterior pituitaries or cerebellar tissue were extracted with 1.0 N acetic acid, boiled, and ultrafiltered through 5000 mol wt cutoff membranes. The eluates were treated with performic acid (which oxidizes disulfide bonds and methionine residues), lyophilized, and reconstituted in saline. Jugular blood was collected from conscious ovariectomized rats before and after intracarotid injection of test substances and was analyzed for PRL, LH, and GH by RIA. Injection of 0.3, 1.0, and 3.0, posterior pituitary equivalents increased plasma PRL levels by 2-, 8-, and 22-fold, respectively. PRL levels peaked within 5 min after the injection and returned to basal levels by 30 min. Plasma LH levels decreased slightly, and GH was unchanged. Cerebellar extracts did not affect plasma hormone levels. Injection of OT induced a 4-fold rise in plasma PRL levels. Oxidation of OT was well as AVP with performic acid abolished any PRL-releasing activity. Injection of beta END increased plasma PRL levels by 7-fold. Treatment of beta END with performic acid caused a 60% loss in its ability to release PRL. Pretreatment of rats with naloxone abolished the PRL-releasing effect of beta END, but did not alter the PRF activity of posterior pituitary extracts. We conclude that posterior pituitary extracts stimulate PRL release in vivo in the presence of an intact dopaminergic inhibition. This stimulation is rapid, dose dependent, and hormone specific. OT, AVP, and beta END do not contribute significantly to the PRF activity in the posterior pituitary extract.
Hyde
J F
JF
Department of Physiology and Biophysics, Indiana University School of Medicine, Indianapolis 46223.
Ben-Jonathan
N
N
D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism / Q000502:physiology; D002457:Cell Extracts / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005561:Formates / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000097:blood; D009270:Naloxone / Q000494:pharmacology; D010052:Ovariectomy; D010084:Oxidation-Reduction; D010121:Oxytocin / Q000378:metabolism / Q000502:physiology; D010904:Pituitary Gland, Posterior / Q000032:analysis* / Q000166:cytology / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013973:Thyrotropin-Releasing Hormone / Q000032:analysis* / Q000097:blood; D001615:beta-Endorphin / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology
D002457:Cell Extracts; D005561:Formates; C008817:peroxyformic acid; D001127:Arginine Vasopressin; D009270:Naloxone; D010121:Oxytocin; D013973:Thyrotropin-Releasing Hormone; D001615:beta-Endorphin; D007986:Luteinizing Hormone